Amphastar Pharmaceuticals Inc vs United Airlines Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while United Airlines Holdings Inc trades at $126.31 (market cap $40.17B). The key difference: United Airlines Holdings Inc is far larger — about 46.5× Amphastar Pharmaceuticals Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | UAL | |
|---|---|---|
Market Cap | $863.95M | $40.17B |
Sector | Health | Industrials |
52-Week High | $30.81 | $136.11 |
52-Week Low | $16.87 | $85.21 |
Enterprise Value | $1.26B | $57.20B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
United Airlines (UAL) trades at $129.56, up 0.34% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $59.07B in 2025 and a net income margin of 5.56%, while valuation metrics like a P/E of 12.13 suggest potential undervaluation. Recent news highlights fleet innovation focus after merger attempts failed, with analyst consensus strongly bullish.
The outlook for UAL is positive, driven by sustained travel demand and cost management, but risks include fuel price volatility and competitive pressures. With 66% of analysts rating it Buy and a consensus price target of $167.73, the stock offers upside, though investors must monitor execution on fuel cost recapture and economic sensitivity.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →